Valerio Therapeutics Société anonyme (ENXTPA: ALVIO)
Health Care · Biotechnology · FR
€0.41
+7.61% today · +609.3% 1Y
Valerio Therapeutics Société anonyme (ENXTPA: ALVIO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $229.28M and employs 25 people.
Over the last twelve months the share price has gained 609.3%, trading between 0.06 and 0.98.
Tweenvest scores Valerio Therapeutics Société anonyme across four factors: quality 24/100, value 34/100, growth 97/100. Its strongest factor is growth.
ALVIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $229.28M
- Revenue (TTM)
- $6.34M
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- 2.14
- 52-week high
- €0.98
- 52-week low
- €0.06
- Avg volume (3M)
- —
- Shares outstanding
- 499.45M
- Employees
- 25
- Next earnings
- —
About Valerio Therapeutics Société anonyme
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on targeting the DNA repair processes crucial for tumor survival. The company's offerings include Beleodaq, an approved medication for peripheral T-cell lymphoma. Their development pipeline features AsiDNA, which is progressing through Phase 1 clinical trials for metastatic melanoma and is also being evaluated for relapsed ovarian cancer through a research collaboration with Gustave Roussy. Furthermore, Valerio Therapeutics is advancing OX401, a preclinical program targeting DNA damage response and immuno-oncology, along with its proprietary platON decoy oligonucleotide platform. The firm also holds a licensing agreement with Acrotech Biopharma LLC.
- ISIN
- FR0010095596
- Founded
- 1997
- Listed since
- Nov 22, 2005
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| PegBio Co., Ltd.SEHK: 2565 | $233.73M | HK$4.69 | -3.10% |
| Alector, Inc.NasdaqGS: ALEC | $232.25M | $2.08 | +2.97% |
| EuBiologics Co., Ltd.KOSDAQ: A206650 | $230.18M | ₩8,420.00 | -0.36% |
| ProQR Therapeutics N.V.NasdaqCM: PRQR | $230.03M | $1.63 | -0.31% |
| Spectral Medical Inc.TSX: EDT | $228.66M | CA$1.11 | -5.53% |
| Evommune, Inc.NYSE: EVMN | $226.83M | $6.25 | -2.50% |
| ImmuneOncia Therapeutics, Inc.KOSDAQ: A424870 | $224.36M | ₩3,300.00 | -4.21% |
| Protalix BioTherapeutics, Inc.NYSEAM: PLX | $223.99M | $2.78 | +2.96% |
Figures last refreshed Oct 11, 2026.